These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 23284936)

  • 21. Natalizumab.
    Berger JR
    Drugs Today (Barc); 2006 Oct; 42(10):639-55. PubMed ID: 17136224
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of natalizumab treatment on Foxp3+ T regulatory cells.
    Stenner MP; Waschbisch A; Buck D; Doerck S; Einsele H; Toyka KV; Wiendl H
    PLoS One; 2008 Oct; 3(10):e3319. PubMed ID: 18836525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [[Natalizumab therapy, 2013].
    Karácsony M; Bencsik K; Vécsei L
    Ideggyogy Sz; 2014 Jul; 67(7-8):220-8. PubMed ID: 25509362
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab.
    Bonig H; Wundes A; Chang KH; Lucas S; Papayannopoulou T
    Blood; 2008 Apr; 111(7):3439-41. PubMed ID: 18195093
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Neuropathology of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy].
    Kanda T
    Brain Nerve; 2015 Jul; 67(7):891-901. PubMed ID: 26160817
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring.
    Khoy K; Mariotte D; Defer G; Petit G; Toutirais O; Le Mauff B
    Front Immunol; 2020; 11():549842. PubMed ID: 33072089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High levels of endothelial ICAM-1 prohibit natalizumab mediated abrogation of CD4
    Soldati S; Bär A; Vladymyrov M; Glavin D; McGrath JL; Gosselet F; Nishihara H; Goelz S; Engelhardt B
    J Neuroinflammation; 2023 May; 20(1):123. PubMed ID: 37221552
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function.
    Jing D; Oelschlaegel U; Ordemann R; Hölig K; Ehninger G; Reichmann H; Ziemssen T; Bornhäuser M
    Bone Marrow Transplant; 2010 Oct; 45(10):1489-96. PubMed ID: 20098455
    [TBL] [Abstract][Full Text] [Related]  

  • 29. L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients.
    Schwab N; Schneider-Hohendorf T; Posevitz V; Breuer J; Göbel K; Windhagen S; Brochet B; Vermersch P; Lebrun-Frenay C; Posevitz-Fejfár A; Capra R; Imberti L; Straeten V; Haas J; Wildemann B; Havla J; Kümpfel T; Meinl I; Niessen K; Goelz S; Kleinschnitz C; Warnke C; Buck D; Gold R; Kieseier BC; Meuth SG; Foley J; Chan A; Brassat D; Wiendl H
    Neurology; 2013 Sep; 81(10):865-71. PubMed ID: 23925765
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Natalizumab Treatment Induces Proinflammatory CD4 T Cells Preferentially in the Integrin β7+ Compartment.
    Nguyen Ky M; Duran A; Hasantari I; Bru A; Deloire M; Brochet B; Ruet A; Schmitt N
    Neurol Neuroimmunol Neuroinflamm; 2023 Nov; 10(6):. PubMed ID: 37739811
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy.
    Wattjes MP; Richert ND; Killestein J; de Vos M; Sanchez E; Snaebjornsson P; Cadavid D; Barkhof F
    Mult Scler; 2013 Dec; 19(14):1826-40. PubMed ID: 24192217
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunomodulatory drugs (natalizumab), worsening of multiple sclerosis, rebound effect and similitude.
    Teixeira MZ
    Homeopathy; 2013 Jul; 102(3):215-24. PubMed ID: 23870382
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
    Bartt RE
    Curr Opin Neurol; 2006 Aug; 19(4):341-9. PubMed ID: 16914971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular diagnostic tests to predict the risk of progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients.
    Rossi F; Newsome SD; Viscidi R
    Mol Cell Probes; 2015 Feb; 29(1):54-62. PubMed ID: 25483260
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function.
    Khatri BO; Man S; Giovannoni G; Koo AP; Lee JC; Tucky B; Lynn F; Jurgensen S; Woodworth J; Goelz S; Duda PW; Panzara MA; Ransohoff RM; Fox RJ
    Neurology; 2009 Feb; 72(5):402-9. PubMed ID: 19188571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Natalizumab therapy for multiple sclerosis.
    Derfuss T; Kuhle J; Lindberg R; Kappos L
    Semin Neurol; 2013 Feb; 33(1):26-36. PubMed ID: 23709210
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug-induced progressive multifocal leukoencephalopathy in multiple sclerosis: European regulators' perspective.
    Anton R; Haas M; Arlett P; Weise M; Balabanov P; Mazzaglia G; Prieto L; Keller-Stanislawski B; Raine J
    Clin Pharmacol Ther; 2017 Aug; 102(2):283-289. PubMed ID: 28001298
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Natalizumab-induced PML: can the beast be tamed?
    Hohlfeld R
    J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1065. PubMed ID: 23475818
    [No Abstract]   [Full Text] [Related]  

  • 39. Natalizumab in multiple sclerosis: discontinuation, progressive multifocal leukoencephalopathy and possible use in children.
    Vitaliti G; Matin N; Tabatabaie O; Di Traglia M; Pavone P; Lubrano R; Falsaperla R
    Expert Rev Neurother; 2015; 15(11):1321-41. PubMed ID: 26513633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Natalizumab and progressive multifocal leukoencephalopathy: migrating towards safe adhesion molecule therapy in multiple sclerosis.
    Bennett JL
    Neurol Res; 2006 Apr; 28(3):291-8. PubMed ID: 16687056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.